IO Biotech Inc [IOBT] stock is trading at $0.89, up 6.09%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IOBT shares have gain 1.74% over the last week, with a monthly amount glided 72.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
IO Biotech Inc [NASDAQ: IOBT] stock has seen the most recent analyst activity on September 30, 2025, when TD Cowen downgraded its rating to a Hold. Previously, Morgan Stanley downgraded its rating to Equal-Weight on September 30, 2025, and kept the price target unchanged to $0.39.
IO Biotech Inc [IOBT] stock has fluctuated between $0.32 and $2.79 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. IO Biotech Inc [NASDAQ: IOBT] shares were valued at $0.89 at the most recent close of the market. An investor can expect a potential return of 237.08% based on the average IOBT price forecast.
Analyzing the IOBT fundamentals
Gross Profit Margin for this corporation currently stands at -0.28% with Operating Profit Margin at -116.71%, Pretax Profit Margin comes in at -121.26%, and Net Profit Margin reading is -122.34%. To continue investigating profitability, this company’s Return on Assets is posted at -2.46, Equity is -2.82 and Total Capital is -4.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8319 points at the first support level, and at 0.7740 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9238, and for the 2nd resistance point, it is at 0.9578.
Ratios To Look Out For
For context, IO Biotech Inc’s Current Ratio is 1.96. As well, the Quick Ratio is 1.96, while the Cash Ratio is 1.41.
Transactions by insiders
Recent insider trading involved Hunter Heidi, Director, that happened on May 30 ’25 when 15000.0 shares were purchased. Chief Medical Officer, Ahmad Qasim Iftikhar completed a deal on Dec 23 ’24 to buy 31350.0 shares. Meanwhile, Chief Executive Officer Zocca Mai-Britt bought 12500.0 shares on Dec 23 ’24.
